Zygmunt Adamski
Overview
Explore the profile of Zygmunt Adamski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wroblewska A, Polanska A, Mojs E, Zaba R, Adamski Z, Danczak-Pazdrowska A
Postepy Dermatol Alergol
. 2023 Nov;
40(5):592-598.
PMID: 38028421
Morphea en coup de sabre and progressive hemifacial atrophy are extremely rare connective tissue disorders causing facial deformity. In extreme cases, morphological disorders are accompanied by symptoms of a clear...
2.
Wozna J, Stepka J, Baloniak A, Adamski Z
Photodermatol Photoimmunol Photomed
. 2023 Nov;
40(1):e12920.
PMID: 37927110
Objective: This survey aimed to evaluate knowledge of photoprotection among individuals from a random group in a resort town in Poland, Kołobrzeg, and explore the correlation between their knowledge and...
3.
Adamski Z, Kanabaj K, Kuzniak A
Postepy Dermatol Alergol
. 2023 Sep;
40(4):496-503.
PMID: 37692276
Psoriasis is a chronic disease, which is associated with numerous genetic and environmental factors. The high prevalence of psoriasis worldwide (2-3% of the general population) and its various comorbidities lead...
4.
Kaczmarek B, Kozlowska M, Narbutt J, Adamski Z, Adamska K, Kaszuba A
Postepy Dermatol Alergol
. 2023 Mar;
40(1):126-133.
PMID: 36909895
Introduction: Chronic venous insufficiency (CVI) is a widespread and serious social problem. The pathogenesis of the disease is multifactorial and one of the important factors in its development is inflammation....
5.
Adamczyk M, Bartosinska J, Raczkiewicz D, Adamska K, Adamski Z, Czubek M, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836209
The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish...
6.
Plagens-Rotman K, Przybylska R, Gerke K, Adamski Z, Czarnecka-Operacz M
Postepy Dermatol Alergol
. 2023 Feb;
38(2):210-213.
PMID: 36751550
Genital herpes is one of the most commonly diagnosed sexually transmitted diseases and the most common factor in the formation of ulcers and erosions within the mucous membranes. It is...
7.
The assessment of prophylactic and therapeutic methods for nail infections in patients with diabetes
Korpowska K, Majchrzycka M, Adamski Z
Postepy Dermatol Alergol
. 2023 Jan;
39(6):1048-1052.
PMID: 36686020
Introduction: Diabetes mellitus is a metabolic disease widespread around the world. It may lead to organ dysfunction, immunodeficiency, vascular complications, and peripheral neuropathy. These factors contribute to susceptibility to fungal...
8.
Polanska A, Lojko-Dankowska A, Czyz A, Adamski Z, Zaba R, Gil L, et al.
Postepy Dermatol Alergol
. 2023 Jan;
39(6):1083-1087.
PMID: 36686018
Introduction: The skin is the typically and predominantly affected organ in patients after allogeneic hematopoietic stem cell transplantation (alloHSCT). The supportive therapy in patients after alloHSCT includes especially ultraviolet protection...
9.
Majchrzycka M, Adamska K, Rachwalska K, Adamski Z
Postepy Dermatol Alergol
. 2023 Jan;
39(6):1106-1109.
PMID: 36686008
Introduction: Psoriasis is a chronic inflammatory disease of the skin, which greatly impairs the patients' self-esteem and consequently leads to a deterioration in their quality of life. Numerous therapeutic options...
10.
Olejnik M, Adamska K, Adamski Z, Dorocka-Bobkowska B
Postepy Dermatol Alergol
. 2023 Jan;
39(6):1151-1156.
PMID: 36686004
Introduction: Psoriasis is a chronic multifactorial dermatosis with an autoimmune and genetic background, with characteristic periods of remission and exacerbation, affecting up to 3% of the population; it is currently...